Latent tuberculosis: Revised treatment guidelines

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 9, 2003, Pages 937-938

  Weir, Erica ^a   Fisman, David N ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULIN;

ADULT; ARTICLE; CASE REPORT; DIRECTLY OBSERVED THERAPY; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNE DEFICIENCY; INFECTION; MALE; PRACTICE GUIDELINE; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0242659204     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. References 1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M. Global burden of tuberculosis. JAMA 1999;282:677-86.
2. Long R, editor. Canadian tuberculosis standards. 5th ed. Ottawa: Canadian Lung Association, Health Canada; 2000.
3. MMWR Update: Adverse event data and revised American Thoracic Society/ CDC recommendations against the use of rifampin and pyrazinamide for the treatment of latent infection - United States, 2003. MMWR 2003;52(31):735-9.
4. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vitonghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-7.
5. Hershfield E. Tuberculosis: 9. Treatment. CMAJ 1999;161:405-11.
6. Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest 2002;122:1292-8.
7. Halsey NA, Coberley JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-92.
8. Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-9.
9. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA 2000;283:2003-7.
10. Arend SM, Engelhard ACF, Groot G, de Boer K, Andersen P, Ottenhoff THM, et al. Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis specific and nonspecific antigens for detection of latent tuberculosis infection in persons with recent tuberculosis contact. Clin Diagn Lab Immunol 2001;8:1089-96.
11. Houston S, Long R, Hoeppner V. Latent tuberculosis treatment [letter]. CMAJ 2002;167(5):452-3.
12. Enarson DA. Tuberculosis: 12. Global disease and the role of international collaboration: CMAJ 2000;162(1):57-61.
13. Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000;162:2033-8.
14. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702.
15. Letvin NL, Bloom BR, Hoffman SL. Prospects for vaccines to protect against AIDS, tuberculosis, and malaria. JAMA 2001;285:606-11.